Lung Cancer Drug Shows Promise Against Ovarian Cancer

Women with ovarian cancer may soon have a powerful new weapon in their fight, thanks to an unexpected discovery about a lung cancer medication.

Mayo Clinic researchers found that ovarian cancer cells activate survival programs within hours of receiving standard PARP inhibitor treatment. This quick reaction helps explain why many tumors eventually stop responding to drugs that initially work well.

The team discovered that a protein called FRA1 switches on genes that help cancer cells adapt and avoid death. It's like the cancer cells have an emergency backup system that kicks in almost immediately.

Dr. Arun Kanakkanthara, an oncology investigator at Mayo Clinic, explains that drug resistance doesn't always develop slowly over months. Cancer cells can flip their survival switches the moment treatment begins.

The research team tested brigatinib, already FDA-approved for certain lung cancers, to see if it could block this early survival response. The results surprised them in the best possible way.

Combining brigatinib with PARP inhibitors worked better than either drug alone. Even more encouraging, the combination only affected cancer cells while leaving healthy cells untouched, suggesting safer treatment with fewer side effects.

The researchers uncovered how brigatinib helps through an entirely new mechanism. Instead of working through traditional DNA repair pathways, it shuts down two key signaling molecules called FAK and EPHA2 that aggressive ovarian cancer cells need to survive.

Why This Inspires

This discovery tackles one of the biggest challenges in ovarian cancer care. Resistance to treatment has left doctors and patients searching for answers, watching initially effective therapies lose their power over time.

The research offers hope for identifying which patients might benefit most. Tumors with higher levels of FAK and EPHA2 responded better to the drug combination, and these markers are often found in more aggressive cancers that need better treatment options most urgently.

Dr. John Weroha, a medical oncologist at Mayo Clinic, emphasizes that targeting resistance before it takes hold could fundamentally change patient outcomes. His team's approach combines laboratory insights with real clinical experience to develop strategies that work in the real world.

Because brigatinib is already FDA-approved for lung cancer, the path to clinical trials for ovarian cancer patients could move faster than with entirely new drugs. Women waiting for better options may not have to wait as long.

This research proves that sometimes the best answers hide in unexpected places, and one cancer's treatment can become another's breakthrough.